肝胆胰疾病中西医结合治疗现状与展望

蒋式骊; 刘平

doi:10.3969/j.issn.1001-5256.2020.01.001

肝胆胰疾病中西医结合治疗现状与展望

DOI: 10.3969/j.issn.1001-5256.2020.01.001

蒋式骊,
刘平

1. 上海中医药大学附属曙光医院肝病研究所肝肾疾病病证教育部重点实验室
2. 上海中医药大学交叉科学研究院

详细信息

中图分类号: R57
计量
- 文章访问数: 1337
- HTML全文浏览量: 39
- PDF下载量: 336
- 被引次数: 0
出版历程
- 收稿日期: 2019-11-21
- 出版日期: 2020-01-20

Current status and perspectives of integrated traditional Chinese and Western medicine therapy for hepatobiliary and pancreatic diseases

Key Laboratory of Liver and Kidney Diseases (Ministry of Education),Institute of Liver Diseases,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

摘要

摘要: 中西医结合治疗是我国临床医疗的重要特色和优势。简述了近年来肝胆胰疾病中西医结合临床及基础研究进展,主要针对常见病如肝纤维化、非酒精性脂肪性肝病、慢性胆囊炎胆石症等,危重病如重症胰腺炎、肝硬化、胰腺癌等,以期客观反映中医对肝胆胰疾病的认识、中西医结合治疗的现状与发展趋势以及存在的问题,为进一步提高临床治疗水平提供参考。
- 肝疾病 /
- 胆道疾病 /
- 胰腺疾病 /
- 中西医结合疗法
Abstract: Integrated traditional Chinese and Western medicine therapy is important feature and advantage of clinical medicine in China.This article reviews the recent advances in the clinical and basic research on hepatobiliary and pancreatic diseases,with a focus on the common diseases such as liver fibrosis,nonalcoholic fatty liver disease,chronic cholecystitis and cholelithiasis,and critical diseases including severe pancreatitis,liver cirrhosis,and pancreatic cancer. We hope to objectively reflect the understanding of hepatobiliary and pancreatic diseases in traditional Chinese medicine,the current status and development trend of integrated traditional Chinese and Western medicine therapy,and existing problems,in order to provide a reference for further improvement of clinical therapeutic level.
- liver diseases /
- biliary tract diseases /
- pancreatic diseases /
- TCM WM therapy

HTML全文

参考文献(25)

[1] ZHANG L, SCHUPPAN D. Traditional Chinese Medicine(TCM)for fibrotic liver disease:Hope and hype[T]. J Hepatol,2014,61(1):166-168.

[2] DONG S,CHEN QL,SU SB. Curative effects of Fuzheng Huayu on liver fibrosis and cirrhosis:A Meta-analysis[J]. Evid Based Complement Alternat Med,2015,2015:125659.

[3] CHEN J,HU Y,CHEN L,et al. The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases[J]. Biomed Pharmacother,2019,114:108846.

[4] GU J,ZHANG Q,XUE D,et al. A randomized controlled study of fuzheng huayu capsule for prevention of esophageal variceal bleeding in patients with liver cirrhosis[J]. Evid Based Complement Alternat Med,2013,2013:534960.

[5] CHEN Y,YANG YP. The role of traditional Chinese medicine in blocking and reversing hepatic fibrosis:Current status,hope,and challenge[J]. J Clin Hepatol,2018,34(4):689-693.(in Chinese)陈艳，杨永平．中医药阻断逆转肝纤维化的现状、希望与挑战[J]．临床肝胆病杂志，2018,34(4):689-693.

[6] MIAO L,YANG WN,DONG XQ,et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Chin J Hepatol,2019,27(7):511-525.(in Chinese)苗亮，杨婉娜，董晓琴，等．安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J]．中华肝脏病杂志，2019,27(7):511-525.

[7] GE XJ,ZHAO CQ,XU LM. Effect of Fuzheng Huayu capsules on survival rate of patients with liver cirrhosis[J]. Chin J Hepatol,2017,25(11):834-890.(in Chinese)戈雪婧，赵长青，徐列明．扶正化瘀胶囊对于肝硬化患者生存率的影响[J]．中华肝脏病杂志，2017,25(11):834-890.

[8] HASSANEIN T,BOX TD,TONG MJ,et al. A phase II,randomized,placebo-controlled,double-blind,multi-center study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis[J]. Gastroenterology,2014,146(5):s261.

[9] Shanghai Cooperative Group of Clinical Trials on Danning Tablets,FAN JG,LIU HY. A multi-centrical clinical trial of DANNING tablet for non-alcoholic fatty liver disease[J]. Int J Dig Dis,2004,24(2):123-125.(in Chinese)上海市胆宁片临床试验协作组，范建高，刘厚钰．胆宁片治疗非酒精性脂肪性肝病的多中心临床试验[J]．国际消化病杂志，2004,24(2):123-125.

[10] CHEN YN,YAN JS,ZHANG YP,et al. Clinical effect of Danning tablets in treatment of nonalcoholic fatty liver disease:A meta-analysis[J]. China Health Nutrition,2018,28(5):281-282.(in Chinese)陈妍凝，晏锦胜，张玉佩，等．胆宁片治疗非酒精性脂肪肝病的Meta分析[J]．中国保健营养，2018,28(5):281-282.

[11] LI HS,FENG Q,ZHU DD,et al. Clinical observation on qushi huayu decoction for 82 cases of non-alcoholic steatohepatitis with phlegm-stasis accumulation syndrome[J]. Chin Arch Tradit Chin Med,2013,31(8):1764-1767.(in Chinese)李红山，冯琴，朱德东，等．祛湿化瘀方治疗痰瘀互结型非酒精性脂肪性肝炎临床观察[J]．中华中医药学刊，2013,31(8):1764-1767.

[12] PENG H,HE Y,ZHENG G,et al. Meta-analysis of traditional herbal medicine in the treatment of nonalcoholic fatty liver disease[J]. Cell Mol Biol(Noisy-le-grand),2016,62(4):88-95.

[13] LIU GB. Analysis of the curative effect of Chinese and Western medicine in the treatment of patients with chronic cholecystitis and gallstone[J]. Cardiov Dis J Integr Tradit Chin Western Med,2016,4(21):193-196.(in Chinese)刘光彬．中西医结合治疗慢性胆囊炎胆石症患者的疗效分析[J]．中西医结合心血管病杂志，2016,4(21):193-196.

[14] CHEN XJ,HU XQ,XU YC,et al. Effect of Dachaihu decoction on the secretion and gene expression of mucin in the gallbladder of guinea pig[J]. Jiangxi J Tradit Chin Med,2015,46(10):34-36.(in Chinese)陈小菁，胡晓晴，许亚超，等．大柴胡汤对豚鼠胆囊黏蛋白分泌及其基因表达的影响[J]．江西中医药，2015,46(10):34-36.

[15] CHEN J,GUO QP. An experimental study on variant herbae artemisiae capillariae decoction for treatment of bile pigment calculus[J]. Chin Remed Clin,2006,6(11):834-836.(in Chinese)陈筠，郭勤平．加味茵陈蒿汤治疗胆色素结石的实验研究[J]．中国药物与临床，2006,6(11):834-836.

[16] YI YX,DING Y,ZHANG Y,et al. Yinchenhao decoction ameliorates alpha-naphthylisothiocyanate induced intrahepatic cholestasis in rats by regulating phase II metabolic enzymes and transporters[J]. Front Pharmacol,2018,9:510-528.

[17] Special Committee of Digestive System Disease,Chinese Association of Integrative Medicine. Consensus statements on the integrated traditional Chinese and Western medicine diagnosis and treatment of cholelithiasis(2017)[J]. Chin J Integr Trad West Med Dig,2018,26(2):132-138.(in Chinese)中国中西医结合学会消化系统疾病专业委员会．胆石症中西医结合诊疗共识意见(2017年)[J]．中国中西医结合消化杂志，2018,26(2):132-138.

[18] Branch of Gastrointestinal Diseases,China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of acute pancreatitis(2017)[J]. J Clin Hepatol,2017,33(11):2052-2057.(in Chinese)中华中医药学会脾胃病分会．急性胰腺炎中医诊疗专家共识意见(2017)[J]．临床肝胆病杂志，2017,33(11):2052-2057.

[19] WANG JJ,CAI CC,ZHANG Q,et al. Effect of Rheum officinale combined with mirabilite on intestinal function and inflammatory factors in patients with severe acute pancreatitis[J].Chin Tradit Patent Med,2019,41(5):1191-1193.(in Chinese)王晶晶，蔡常春，张晴，等．联合使用大黄、芒硝对重症急性胰腺炎患者肠道功能和炎症因子的影响[J]．中成药，2019,41(5):1191-1193.

[20] WANG FB,DING JT,FAN H. Effect of biliary and pancreatic duct stenting combined Danning Tablets on biliary acute recurrent pancreatitis[J]. Guangxi Med J,2018,40(20):2414-2416.(in Chinese)王富兵，丁江涛，范辉．胆胰管内支架植入联合胆宁片治疗胆源性急性复发性胰腺炎的效果[J]．广西医学，2018,40(20):2414-2416.

[21] LI L,LIU J,QIN K. Meta-analysis of effectiveness of Qingyi Decoction in treatment of severe acute pancreatitis[J]. Chin J Exp Med Formul,2015,21(23):207-211.(in Chinese)李磊，刘静，秦侃．清胰汤治疗重症急性胰腺炎的临床疗效的Meta分析[J]．中国实验方剂学杂志，2015,21(23):207-211.

[22] SIEGEL R,MA J,ZOU Z,et al. Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.

[23] LU JZ,CAO XT,WANG LL. Clinical effect of traditional Chinese medicine treatment in advanced pancreatic cancer:A meta-analysis[J]. China J Tradit Chin Med Pharma,2014,29(2):441-443.(in Chinese)路军章，曹秀堂，王莉莉．中医药治疗中晚期胰腺癌的Meta分析[J]．中华中医药杂志，2014,29(2):441-443.

[24] LIU LM. Opportunities and challenges for integrated traditional Chinese and Western medicine therapy for pancreatic cancer[J]. Chin J Integr Trad West Med,2019,39(1):18-20.(in Chinese)刘鲁明．中西医结合治疗胰腺癌的机遇与挑战[J]．中国中西医结合杂志，2019,39(1):18-20.

[25] SONG LB,LIU LM,CHEN H,et al. Retrospective study of232 post-operative patients with pancreatic cancer treated by modified qingyi huaji formula combined with western medicine[J]. Chin J Integr Trad West Med,2018,38(8):932-935.(in Chinese)宋利斌，刘鲁明，陈颢，等．清胰化积方化裁联合西药治疗232例胰腺癌术后患者回顾性研究[J]．中国中西医结合杂志，2018,38(8):932-935.

施引文献

资源附件(0)

访问统计